Chemistry:Efpeglenatide

From HandWiki
Revision as of 22:19, 5 February 2024 by Dennis Ross (talk | contribs) (link)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Efpeglenatide
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Efpeglenatide is a GLP-1 receptor agonist under development for the treatment of type 2 diabetes and obesity and reducing the risk of cardiovascular incidents in people with these conditions.[1][2][3][4][5][6][7] Its developer is Hanmi Pharmaceutical.[8]

References

  1. ↑ Frias, Juan Pablo; Choi, JaeDuk; Rosenstock, Julio; Popescu, Luiza; Niemoeller, Elisabeth; Muehlen-Bartmer, Isabel; Baek, Seungjae (7 July 2022). "Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial". Diabetes Care 45 (7): 1592–1600. doi:10.2337/dc21-2656. PMID 35671039. 
  2. ↑ Lam, Carolyn S.P.; Ramasundarahettige, Chinthanie; Branch, Kelley R.H.; Sattar, Naveed; Rosenstock, Julio; Pratley, Richard; Del Prato, Stefano; Lopes, Renato D. et al. (22 February 2022). "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial". Circulation 145 (8): 565–574. doi:10.1161/CIRCULATIONAHA.121.057934. PMID 34775781. 
  3. ↑ Gerstein, Hertzel C.; Li, Zhuoru; Ramasundarahettige, Chinthanie; Baek, Seungjae; Branch, Kelley R.H.; Del Prato, Stefano; Lam, Carolyn S.P.; Lopes, Renato D. et al. (28 March 2023). "Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial" (in en). Circulation 147 (13): 1004–1013. doi:10.1161/CIRCULATIONAHA.122.063716. ISSN 0009-7322. PMID 36802715. 
  4. ↑ Pratley, Richard E.; Kang, Jahoon; Trautmann, Michael E.; Hompesch, Marcus; Han, OakPil; Stewart, John; Sorli, Christopher H.; Jacob, Stephan et al. (November 2019). "Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study". Diabetes, Obesity & Metabolism 21 (11): 2429–2439. doi:10.1111/dom.13824. ISSN 1462-8902. PMID 31264757. 
  5. ↑ Pratley, Richard E.; Jacob, Stephan; Baek, Seungjae; Trautmann, Michael E.; Hompesch, Marcus; Han, OakPil; Stewart, John; Sorli, Christopher H. et al. (1 January 2022). "Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline" (in en). BMJ Open Diabetes Research and Care 10 (1): e002207. doi:10.1136/bmjdrc-2021-002207. ISSN 2052-4897. PMID 35042751. PMC 8768911. https://drc.bmj.com/content/10/1/e002207. 
  6. ↑ Gerstein, Hertzel C.; Li, Zhuoru; Ramasundarahettige, Chinthanie; Baek, Seungjae; Branch, Kelley R.H.; Del Prato, Stefano; Lam, Carolyn S.P.; Lopes, Renato D. et al. (28 March 2023). "Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial". Circulation 147 (13): 1004–1013. doi:10.1161/CIRCULATIONAHA.122.063716. PMID 36802715. 
  7. ↑ Gerstein, Hertzel C.; Sattar, Naveed; Rosenstock, Julio; Ramasundarahettige, Chinthanie; Pratley, Richard; Lopes, Renato D.; Lam, Carolyn S.P.; Khurmi, Nardev S. et al. (2 September 2021). "Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes" (in en). New England Journal of Medicine 385 (10): 896–907. doi:10.1056/NEJMoa2108269. ISSN 0028-4793. PMID 34215025. 
  8. ↑ Pharmaceutical, Hanmi. "Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"". www.prnewswire.com (Press release). Retrieved 5 November 2023.



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Efpeglenatide&oldid=3326280"